InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,595.76
(
0.75%
)
US TECH 100
18,928.80
(
0.00%
)
Dow Jones
41,096.77
(
0.58%
)
Brent Oil
72.06
(
0.12%
)
Bitcoin
57,855.01
(
-0.48%
)
Post# of 3195
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

paulyboy

Send PM Follow Ignore
Followers 3
Posts 663
Boards Moderated 0
Alias Born 09/19/2006

paulyboy

Re: None

Tuesday, 05/28/2013 8:54:43 PM

Tuesday, May 28, 2013 8:54:43 PM

Post# of 3195
ALXA has $10-12 outperform targets from Dec 2012(pre-approval) through 2013 EU partnership from ROTH, JMP and Piper.

Noted in the upgrades are the targets based on Approvals in US and EU, $5 million from Ferrer.

Not noted in any of the targets is the new Teva deal bringing in $40 mil (30 to ALXA) and almost 200 mil in milestones.


I expect new targets above $15 a share to come out soon. IMO below are my thoughts on those new price targets

Piper $10 New Target $16
JMP $12 New Target $19
Roth $10 New Target $15

Roth also noted that in the previous upgrade that any new drug added to or continuing development is not included their $10 target, but will add more upside on the target price when announced.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up